In humans, neutralizing TNFα using an anti-TNFα monoclonal antibody corrects endothelial dysfunction observed in chronic inflammatory diseases, such as RA and systemic vasculitis [11,12]. The gene discussed is TNF; the disease is rheumatoid arthritis.